In the beginning of 2020, when MedWatch interviewed the people behind the young biotech firm Biograil, they indicated that they were looking for partners within the pharmaceutical industry. Now – just under a year later – they managed to poach the first one.
This week Biograil presents the announcement that it has entered into a collaboration with the pharmaceutical leg of the giant Johnson & Johnson – Janssen.
Get full access for you and your coworkers.Start a free company trial today
Already a member? Log in.